Keywords: Pozen, Desitin Arz, MT 400, Sumatriptan and naproxen, Migrain, EU license

Pozen out-licenses migraine drug candidate to Desitin for EU

Article | 09 May 2012

Print This

US drugmaker Pozen (Nasdaq: POZN) has entered into a license agreement with Germany’s Desitin Arzneimittel GmbH, for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in